Q’Apel Medical Inc. Receives CE Mark for Walrus Balloon Guide Catheter

Q’Apel Medical Inc. has received the CE Mark under MDR for their Walrus Balloon Guide Catheter (BGC), which is a medical device utilized in the treatment of patients who suffer from acute ischemic stroke. The Walrus BGC has already been in use in the United States since 2019 and has successfully treated over 20,000 patients.
 
The Walrus BGC is a unique development in the field of Mechanical Thrombectomy procedures. It provides physicians with not only the known benefits of BGC use clinically, but unique to Walrus, superior ease of use in preparation in these urgent procedures. The device also enables physicians to navigate the catheter into a more distal location easily and safely compared to other systems, which is associated with improved patient outcomes from stroke.
 
“We look forward to the same performance and loyalty around Walrus we have been fortunate to experience in the United States,” said King Nelson, Q’Apel Medical’s CEO. “The anticipation of Walrus in our international markets has been enormous.”
 
Jodie Fam, Q’Apel Medical’s Chief Marketing Officer and GM International, also expressed excitement about the CE Mark certification and the company’s expansion into international markets, stating, “We are thrilled to be entering the EU and other international markets with Walrus and providing more physicians in more countries the unparalleled performance of our flagship catheter. This CE Mark certification represents a significant growth milestone for Q’Apel Medical providing access to new markets.”
 
The company’s success in the U.S. market, coupled with the Walrus BGC’s unique benefits, makes it a promising addition to the global medical community’s arsenal of tools for treating patients suffering from acute ischemic stroke.